Summary
The AI-generated claims provided are largely about bromocriptine for multiple non–CYCLOSET indications (e.g., prolactinomas, Parkinson’s disease, acromegaly, lactation suppression). The supplied FDA label excerpt is for CYCLOSET (bromocriptine mesylate) indicated only for improving glycemic control in adults with type 2 diabetes mellitus. Therefore, most provided indication claims are not supported by the supplied label text.
Category Scores
Accurate Statements
CYCLOSET is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Label excerpt 1 INDICATIONS AND USAGE: “CYCLOSET is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.”
Unsupported Statements
Bromocriptine is a dopamine agonist.
No supporting statement for this mechanism is present in the supplied label excerpts (only the CYCLOSET type 2 diabetes indication and related trial/pediatric/geriatric/pregnancy limitation excerpts were provided).
Bromocriptine is indicated for prolactin-secreting pituitary tumors (prolactinomas) to reduce prolactin levels.
Not supported by the supplied CYCLOSET label excerpt, which addresses only type 2 diabetes glycemic control.
Bromocriptine is indicated for prolactin-secreting pituitary tumors (prolactinomas) to shrink tumor size.
Not supported by the supplied CYCLOSET label excerpt.
Bromocriptine is indicated for hyperprolactinemia that causes reproductive and endocrine problems such as amenorrhea, infertility, and galactorrhea.
Not supported by the supplied CYCLOSET label excerpt.
Bromocriptine is indicated for Parkinson’s disease as symptomatic treatment to help manage motor symptoms.
Not supported by the supplied CYCLOSET label excerpt.
Bromocriptine is indicated for treating amenorrhea when high prolactin leads to missed or absent menstrual periods.
Not supported by the supplied CYCLOSET label excerpt.
Bromocriptine is indicated for treating infertility related to prolactin excess.
Not supported by the supplied CYCLOSET label excerpt.
Bromocriptine is indicated for treating galactorrhea (milk discharge when not pregnant or breastfeeding) when caused by high prolactin.
Not supported by the supplied CYCLOSET label excerpt.
Bromocriptine can be used in acromegaly in some settings to control excess growth hormone activity.
Not supported by the supplied CYCLOSET label excerpt.
In Parkinson’s disease, bromocriptine is used to treat motor symptoms by acting on dopamine receptors.
Not supported by the supplied CYCLOSET label excerpts.
Bromocriptine may be used alone or with other antiparkinson medications depending on disease stage and symptom control goals.
Not supported by the supplied CYCLOSET label excerpt.
Bromocriptine has been used to suppress lactation to prevent lactation medically in specific clinical contexts.
Not supported by the supplied CYCLOSET label excerpt.
Suppressing lactation with bromocriptine depends on local guidance and patient-specific risk factors.
Not supported by the supplied CYCLOSET label excerpt.
Bromocriptine generally requires careful clinical oversight in people with significant cardiovascular disease.
No such warning/precaution statement is present in the supplied label excerpts.
Bromocriptine generally requires careful clinical oversight in people with uncontrolled hypertension.
No such warning/precaution statement is present in the supplied label excerpts.
Bromocriptine generally requires careful clinical oversight in people with certain psychiatric conditions.
No such warning/precaution statement is present in the supplied label excerpts.
Bromocriptine generally requires careful clinical oversight in pregnancy-related risk factors.
No such warning/precaution statement is present in the supplied label excerpts.
Indication choice and dosing of bromocriptine are individualized.
Not supported by the supplied label excerpts (the provided excerpts do not include dosing details or individualized dosing language for bromocriptine).
Contradictions
Low
AI Statement
Bromocriptine is indicated for prolactin-secreting pituitary tumors (prolactinomas) to reduce prolactin levels.
Label Reference
Supplied label excerpt 1 INDICATIONS AND USAGE: CYCLOSET indication is “to improve glycemic control in adults with type 2 diabetes mellitus.”
Low
AI Statement
Bromocriptine is indicated for Parkinson’s disease as symptomatic treatment to help manage motor symptoms.
Label Reference
Supplied label excerpt 1 INDICATIONS AND USAGE: CYCLOSET indication is “to improve glycemic control in adults with type 2 diabetes mellitus.”
Important Omissions
The only supported FDA-labeled indication for CYCLOSET in the provided label excerpt is glycemic control in adults with type 2 diabetes mellitus (adjunct to diet and exercise). The AI list omits this label-specific limitation and instead asserts multiple other bromocriptine indications.
Importance:
High
Safety Assessment
Potential Patient Risk:
High
The supplied label excerpt supports only CYCLOSET for adjunctive glycemic control in adults with type 2 diabetes. The AI-provided content asserts many other indications and uses for bromocriptine (tumors, Parkinson’s disease, acromegaly, lactation suppression, etc.) without support from the provided label text, creating a high likelihood of label-inaccurate prescribing guidance.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most indication statements do not match the provided CYCLOSET label excerpt (type 2 diabetes glycemic control only).
Suggested Improvement
Limit indication statements to the FDA-labeled use in the provided label excerpt: adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.